Table 2.

Mean change (SD) from baseline in BMI (kg/m²) according to baseline BMI and treatment group

FINCH 1
	FIL200	FIL100	ADA	PBO
BMI < 25 kg/m2	n = 214	n = 203	n = 139	n = 197
Week 12	0.1 (0.57)	0.2 (0.68)	0.1 (0.65)	0.2 (0.63)
Week 24	0.2 (0.87)	0.5 (0.82)	0.3 (0.92)	0.2 (0.80)
BMI 25 to < 30 kg/m2	n = 137	n = 162	n = 106	n = 155
Week 12	0.2 (0.71)	0.0 (0.78)	0.0 (0.67)	0.0 (0.74)
Week 24	0.2 (1.06)	0.1 (1.13)	0.0 (0.89)	0.1 (0.89)
BMI ≥ 30 kg/m2	n = 124	n = 115	n = 80	n = 123
Week 12	0.2 (1.01)	0.1 (0.92)	0.1 (0.79)	0.1 (0.99)
Week 24	0.2 (1.53)	0.2 (1.26)	0.0 (1.29)	0.0 (1.30)

FINCH 2
	FIL200	FIL100	PBO
BMI < 25 kg/m2	n = 39	n = 38	n = 42
Week 12	0.3 (0.55)	0.1 (0.93)	0.0 (0.41)
Week 24	0.4 (0.70)	0.3 (1.13)	0.0 (0.92)
BMI 25 to < 30 kg/m2	n = 42	n = 46	n = 42
Week 12	0.2 (0.84)	0.2 (0.89)	0.2 (1.15)
Week 24	0.1 (1.10)	0.5 (1.13)	0.1 (1.60)
BMI ≥ 30 kg/m2	n = 66	n = 69	n = 64
Week 12	0.1 (1.28)	0.2 (1.19)	− 0.3 (0.98)
Week 24	0.0 (2.21)	0.7 (1.30)	− 0.3 (1.46)

FINCH 3
	FIL200 + MTX	FIL100 + MTX	FIL200	MTX
BMI < 25 kg/m2	n = 154	n = 73	n = 81	n = 152
Week 12	0.2 (0.73)	0.4 (0.95)	0.4 (0.74)	0.1 (0.86)
Week 24	0.3 (1.05)	0.7 (1.26)	0.8 (1.14)	0.2 (1.01)
BMI 25 to < 30 kg/m2	n = 134	n = 69	n = 77	n = 132
Week 12	0.2 (0.86)	0.5 (1.35)	0.4 (0.99)	0.3 (0.79)
Week 24	0.4 (1.27)	0.4 (1.09)	0.8 (1.55)	0.4 (1.04)
BMI ≥ 30 kg/m2	n = 128	n = 65	n = 52	n = 132
Week 12	0.2 (1.06)	0.2 (1.35)	0.5 (0.90)	− 0.1 (1.00)
Week 24	0.3 (1.37)	0.4 (1.77)	0.5 (1.14)	0.0 (1.65)

ADA adalimumab, BMI body mass index, FIL(100/200) filgotinib 100/200 mg, MTX methotrexate, PBO placebo